Cargando…
Mifepristone Treatment Promotes Testicular Leydig Cell Tumor Progression in Transgenic Mice
SIMPLE SUMMARY: Recently, the antiprogestin activity of selective progesterone receptor (PR) modulator mifepristone (MF) has proven unsuccessful as a potential anti-cancer agent in various clinical trials. Herein, we analyzed the effects of MF treatment on Leydig cell tumor (LCT) progression in a tr...
Autores principales: | Ponikwicka-Tyszko, Donata, Chrusciel, Marcin, Pulawska, Kamila, Bernaczyk, Piotr, Sztachelska, Maria, Guo, Peilan, Li, Xiangdong, Toppari, Jorma, Huhtaniemi, Ilpo T., Wołczyński, Slawomir, Rahman, Nafis A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694279/ https://www.ncbi.nlm.nih.gov/pubmed/33158280 http://dx.doi.org/10.3390/cancers12113263 |
Ejemplares similares
-
Molecular mechanisms underlying mifepristone's agonistic action on ovarian cancer progression
por: Ponikwicka-Tyszko, Donata, et al.
Publicado: (2019) -
Extragonadal FSHR Expression and Function—Is It Real?
por: Chrusciel, Marcin, et al.
Publicado: (2019) -
Revisiting the expression and function of follicle-stimulation hormone receptor in human umbilical vein endothelial cells
por: Stelmaszewska, Joanna, et al.
Publicado: (2016) -
Functional Implications of Estrogen and Progesterone Receptors Expression in Adenomyosis, Potential Targets for Endocrinological Therapy
por: Sztachelska, Maria, et al.
Publicado: (2022) -
New Insights on the Progesterone (P4) and PGRMC1/NENF Complex Interactions in Colorectal Cancer Progression
por: Kamińska, Joanna, et al.
Publicado: (2023)